Colorectal SurgeryPhase 4NCT03537989
Restricted Fluid Therapy in Colorectal Surgery
A Phase 4 study testing Saline in people with Colorectal Surgery and Postoperative Complications, run by Holbaek Sygehus.
Trial summary
This is a protocol for a trial carried out from 1999 to 2002. At that time, surgical patients received a large volume of intravenous saline during operations on the colon or the rectum, often so much fluid that their bodyweight increased by 4-6 kilograms. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Surgery, Postoperative Complications
- What is being tested?
- Saline
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 172 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 1999to 31 Aug 2001
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients scheduled for planned surgery on the colon or the rectum
- ASA group 1-3
Who cannot join
- Patients unable to give informed consent (mental disorders, dementia, language problems)
- Patients with:
- Diabetes mellitus
- Renal insufficiency
- Disseminated cancers or secondary cancers
- Inflammatory bowel disease
Show all 9Show fewer
- Diseases hindering epidural analgesia
- Alcohol consumption more than 35 drinks pr. Week
- Pregnant and lactating woman.
About this study
Official title: Perioperative Fluid Treatment in Colorectal Surgery
This is a protocol for a trial carried out from 1999 to 2002. At that time, surgical patients received a large volume of intravenous saline during operations on the colon or the rectum, often so much fluid that their bodyweight increased by 4-6 kilograms. We hypothesized; that a restricted fluid regimen could prevent the development of cardiopulmonary complications and improve wound healing including the healing of an anastomosis of the gut.
We designed a clinical randomized assessor blinded multi-center trial comparing a restricted fluid regimen to a standard fluid regimen, the difference being the volume of saline administered to the patients. Patients undergoing surgery on the colon or the rectum were included after informed oral and written consent.
Read more
The restricted regimen aimed at zero-fluid balance with allowance for a body weight increase of 1 kg. The standard regimen was a bit "dryer" than the actual standard; our patients in the standard group received saline causing a body weight increase of only 3-4 kg. The fluid therapy started at midnight the day of operation, went on through the operation and continued on the wards until discharge. The patients were encouraged to eat and drink as much and as soon as possible after the operation.
The primary outcome was the number of patients who died or suffered a complication measured within 30 days of surgery. We looked at all complications, but especially heart and lung complications and complications related to the healing of wounds and anastomosis.
The patients was examined in the outpatient clinic after 30 days, and in addition, blinded assessors were reviewing the medical files for registration of postoperative complications.
The results are published in The Annals of Surgery 2003; 238(5)641-48. The restricted regimen nearly halved the number of patients with complications, and heart and lung complications were almost eliminated.
Other investigators confirmed the results, and a more restricted approach to fluid therapy to surgical patients has been implemented worldwide.
Read the detailed description
Aim:
To show the effect of a restrictive fluid regime compared to a standard regime by the frequency of complications in patients undergoing colorectal surgery.
Background:
Previous studies have risen suspicions of fluid balance, and especially a large amount of water and NaCl administration, can be a significant factor in developing postoperative complications (1, 2).
In 1990 in Critical Care Magazine, Lowell et al. described patients who in transferring to intensive therapy had an increased weight of > 10% of their preoperative weight, had a significantly higher mortality rate of 31.6 % than patients with an increased weight of < 10%, who only had a mortality rate of 10.3 %.
Some studies, have described, how all patients undergoing gastroenterological operations increase their body weight by 2-4% of the preoperative weight during the first 24 hours following surgery due to the perioperative saline intravenously (2, 3). The patients have been given a median of 6-7 L saline intravenously during the day of operation. This is fully comparable to other studies (3, 5).
Based on previous guidelines in anesthesiological departments, a volume of saline of 15 ml/kg bodyweight was administered during the first hour of surgery, and 7.5 ml/kg during the following hours. Furthermore, any blood loss was replaced by 2.5 ml saline per ml blood lost (6-9).
The patients in the study by Beier-Holgersen et al. returned to their preoperative weight after 4-5 days. In this material of 60 patients, six patients developed leakage of the bowel anastomosis, and two patients died from AMI and ARDS. Nine patients with severe complications had a weight gain of 6-14%.
The increased postoperative fluid retention results in increased universal edema, which can significantly affect the tissue's microcirculation and oxygenation. This may have influenced the healing of intestinal anastomoses and the development of cardiovascular and pulmonary complications, which typically occurred during the third postoperative day. Based on this, it is therefore relevant to investigate whether perioperative intervention against fluid administration can improve the postoperative course.
Design:
Prospective randomized multicenter study with stratification for each center. Block randomization with four patients per block. It is necessary to incorporate several centers for the investigation to be finished within a reasonable time.
Material:
Two x 70 patients scheduled for colorectal resection. The number is determined from previous works (1, 2) finding a total complication rate of at least 30% after colorectal resection in post-operatively early-nourished patients. The investigators wish to reduce this to 10% (MIREDIF = 20%). The risk of Type 1 error (5%) is set low to avoid overlooking a possible gain. The risk of Type 2 error is set at 20% (power at 80%).
As the material is unlikely to meet the normal distribution, the number of participant's increases to 70 in each group, i.e. 140 patients must be included. In order to reduce the variation, each center must include at least 16 patients (which means that up to nine centers have to participate).
Method:
- Patients are included preoperatively after informed consent. An investigator at the local center randomize the patients to either standard fluid treatment or restrictive perioperative fluid treatment. The main difference between the two regimes is that less isotonic saline is administered in the restrictive regime. Anesthesia and postoperative nutrition regimes are the same in the two groups. The patients are ASA and Apache 2 scored.
- Weight registration: The patient is weighed on the same set of scales at the time of hospitalization (entry weight), after bowel cleansing, and in the morning on the day of operation (preoperative weight). Hereafter daily weighing every postoperative morning.
- Blood tests: Blood is withdrawn on the day of hospitalization, on the day of operation in the morning, on arrival in the recovery ward and the following 7 days (or until discharged).
- Anesthesia: Patients must fast for food from midnight before surgery, but they can have clear fluids up to 2 hours preoperatively, but max. 500 ml from midnight. Premedication is a tablet of Triazolam 0.125 mg with 50-100 ml of water by mouth. Combined epidural and general anesthesia are used: An epidural catheter is inserted corresponding to TH10-12, tested with Lidocaine 2% and adrenaline 3-4 ml. After 3-5 minutes this is supplemented with refracted doses of Bupivacaine 0.5% until the blockade is sufficient (often about 8-12 ml). Continuous infusion of Bupivacain is administered 0.5%, 4-8 ml/hour. Finally, a bolus injection of 2 mg Morphine is administered. General anesthesia is induced with Fentanyl 5μg/kg, Thiopental 3-4 mg/kg and Rocuronium (Esmeron®) 0.6 mg/kg (all doses are modified according to each patient's needs and cardiovascular condition). Anesthesia is maintained with Isoflurane 0.2-0.4% end-tidal concentration in oxygen / atmospheric air (inspiratory oxygen concentration 30-35%). The neuromuscular block can be reverted with neostigmine when needed. Hypotension Diagnosis and Treatment: Detailed guidelines for clinical treatment and handling are given in the case report forms (CRF).
- Perioperative fluid treatment: During operation, fluid is submitted and recorded in the CRF. Fluid balance is calculated at the end of anesthesia.
- Monitoring: Standard anesthesia monitoring as recommended by Danish Anesthesiological Society. A central vein catheter (CVK) is placed if needed after the initiation of anesthesia to measure central venous pressure (CVP) until the patient is discharged from the recovery ward. Arterial blood gases and hematocrit are withdrawn immediately after the initiation of anesthesia, immediately after arriving at the recovery ward and before the patient is transferred to the surgical ward, in addition to clinical needs.
- Surgery: Surgery is performed in accordance with the department's routines. During the surgery, a nutritional feeding tube is inserted in the duodenum for postoperative enteral nutrition. If the tube cause nausea, the tube is removed and the patient will consume nutrition according to ability by mouth. Antibiotic prophylaxis, bowel cleansing, physiotherapy, etc. follow the usual guidelines of the respective departments.
- Postoperative fluid treatment and nutrition during the day of operation: Fluid recordings continue from the end of the anesthesia, on the recovery ward and for the rest of the day of operation. On the day of operation, 600 ml of Nutri-concentrated 75 is given in the feeding tube. Nutri-concentrated 75 contains 200 kcal and 7.5 g protein per 100 ml. 1000 ml pr. Day cover the recommended daily allowances for vitamins and minerals.
- Fluid treatment and nutrition in the following days: Nutri-concentrated 75® 1000 ml/day is continued the first three postoperative days. Thereafter the patient is expected to eat normally. The fluid regime in the restrictive group assessed based on the patient's weight, ability to drink independently and blood samples. The standard regime follows the department's usual postoperative regime.
- Postoperative analgesia: The basis is an epidural infusion of the standard mixture of Bupivacain-Morphine (5 mg Morphine + 250 mg Bupivacain in NaCl to the volume of 100 ml), 4-8 ml/hour. In addition, Morphine 5-10 mg p.n. If there are no contraindications, Paracetamol or NSAID can be administered (orally or rectally). The epidural pain treatment is continued postoperatively for a maximum of 4 days, after which the epidural catheter is removed. If the patient need analgesics hereafter, opioid is given by mouth or intravenously as well as Paracetamol and/or NSAIDs.
- For the treatment of nausea the following may be given: Ondansetron (Zofran®), Cisapride (Prepulsid®), Metoclopramide (Primperan®) or DHB.
- A postoperative outpatient visit with the investigating doctor is planned 4 weeks after the surgery. Postoperative complications are registered.
Ethics:
Participation in the project is voluntary and inclusion is after informed consent. Consent can be withdrawn at any time without further explanation, and without this affecting the patient's treatment in any way.
There is no risk associated with participation in the project, but discomfort associated with additional blood sampling for the project, no more than 4-5 times. However, these blood samples will preferably be taken from the CVK, so the patient avoids being stabbed unnecessarily.
In the long term, a treatment benefit is possible and this appears to outweigh the discomfort mentioned above.
The project is registered with the Scientific Ethics Committee (multicenter study) and The Danish Data registration agency in accordance with applicable guidelines. All person-identifiable data is destroyed after the project is completed.
Addendum to the protocol written during the patient inclusion and before the trial was completed.
Hypothesis:
Both too little and too much fluid administered intravenously may be harmful to the cardiac function (low oxygen supply and congestion) and cause cardiovascular complications: Postoperatively developed arrhythmias, AMI, pneumonia, pulmonary congestion, postoperatively developed pleural exudate, pulmonary edema or ARDS.
Both too little and too much fluid administered intravenously may be harmful to tissue healing (low oxygen supply and interstitial edema) and cause complications related to tissue healing and infection: Infections of the wound, bursting of the wound (superficial and deeper), leakage from the anastomosis and separation of stoma.
Randomization:
The investigating surgeon or anesthesiologist perform the randomization by opening consecutively numbered opaque envelopes. The randomization is stratified for each center and for colonic and rectal surgery the latter by opening an envelope with highest number for rectal surgical patients, and with lowest number for colonic patients.
Blinding:
Specialist surgeons reading the medical journals censored for all information about randomization group, fluid therapy given or bodyweight measurements will perform a blinded assessment for the primary outcome.
Two doctors will evaluate each patient file, and in case of disagreement, a third will decide the outcome.
Plan for analysis:
An intention to treat analysis will be performed for the primary outcome for all patients included in the trial whether or not they met a post randomization exclusion criterion, and therefore did or did not receive the allocated treatment.
A per protocol analysis will be performed for the primary outcome for all patients fulfilling the in- and exclusion criteria whether or not they adhered to the protocol.
Subgroup analysis will be performed for the patients with Major-, Minor-, Cardio-pulmonic- and tissue-healing complications.
- Conditions
- Colorectal Surgery, Postoperative Complications
- Being tested
- Saline
- Keywords
- fluid therapy, Restricted fluid therapy, saline
- Medical subject headings
- Postoperative Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SalineDrug
Also called NaCl 0.9%
To reduce the volume of saline administered during surgery of the colon and the rectum
| Study group | Role | What they receive |
|---|---|---|
| Restricted group | Experimental | Oral fluid to 2 h before surgery. Intra-operatively: Glucose 5% (500 ml - volume drunk during fast); HAES 6% for blood loss volume to volume; IV-medicine in saline 0.9% for anesthesia and antibiotics. Blood products after current rules.
Postoperatively: 1000 ml glucose containing fluid in the recovery room. Free oral intake of fluid and food as well as enteral feeding by tube 500 ml.
In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. If less than 1500 ml fluid pr. mouth supplement with VI-fluid.
Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Goal: zero fluid balance with up to 1-kilogram body weight increase.
Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid. Receives: Drug: Saline |
| Standard group | Active comparator | Oral fluid to 2 h before surgery. Intra-operatively: Saline 500 ml for fasting; 500 ml HAES 6% for the epidural, Saline for the third space: 7 ml/kg/h first hour, 5 ml/kg/h 2.-3. Hour, 3 ml/kg/h subsequent hours. 1000-1500 ml Saline replaced lost blood up to 500 ml, additional HAES 6% for additional blood loss; IV-medicine in saline.
Postoperatively: 1000-2000 ml isotonic fluid in the recovery room. Free oral fluid and food as well as enteral feeding by tube 500 ml.
In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. Supplemental iv-fluid according to department rules. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid.
Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid. Receives: Drug: Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative complications and mortality
The complications was defined by protocol.
Measured: After 30 days of follow-up
Secondary outcomes (2)
Cardiopulmonary complications
AMI, debut of cardiac arrhythmias, pulmonary congestion, pulmonary oedema, ARDS, pneumonia
Measured: After 30 days of follow-up
Complications related to tissue healing
Wound complications and anastomotic leak
Measured: After 30 days of follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2018
- Study start1 Nov 1999
- Primary completion31 Aug 2001
- Study completion31 Aug 2001
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Colorectal SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 172 participants (actual)
Sponsor and investigators
- Lead sponsor
- Holbaek Sygehus
- Sponsor type
- University, hospital or other
- Collaborators
- Bispebjerg Hospital, University Hospital, Gentofte, Copenhagen, Glostrup University Hospital, Copenhagen, Herlev Hospital, Hillerod Hospital, Denmark, Vejle Hospital, Aalborg University Hospital, Zealand University Hospital
- Responsible party
- Principal investigator, Birgitte Brandstrup, Holbaek Sygehus
- Investigators
- Birgitte Brandstrup, PhD, Principal investigator, Holbaek Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03537989
- Sponsor's protocol ID
- 1
- Status last verified
- Oct 2018
- First submitted
- 11 May 2018
- Last updated
- 5 Oct 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: We do not mind sharing the data
Publications
Lowell JA, Schifferdecker C, Driscoll DF, Benotti PN, Bistrian BR. Postoperative fluid overload: not a benign problem. Crit Care Med. 1990 Jul;18(7):728-33. doi: 10.1097/00003246-199007000-00010.
PubMed 2364713Beier-Holgersen R, Boesby S. Influence of postoperative enteral nutrition on postsurgical infections. Gut. 1996 Dec;39(6):833-5. doi: 10.1136/gut.39.6.833.
PubMed 9038665Nielsen OM, Engell HC. Increased glomerular filtration rate in patients after reconstructive surgery on the abdominal aorta. Br J Surg. 1986 Jan;73(1):34-7. doi: 10.1002/bjs.1800730113.
PubMed 3947870Rasmussen LA, Rosenberg J, Crawford ME, Kehlet H. [Perioperative fluid therapy. A quality control study]. Ugeskr Laeger. 1996 Sep 16;158(38):5286-90. Danish.
PubMed 8966776Vamvakas EC, Carven JH, Hibberd PL. Blood transfusion and infection after colorectal cancer surgery. Transfusion. 1996 Nov-Dec;36(11-12):1000-8. doi: 10.1046/j.1537-2995.1996.36111297091746.x.
PubMed 8937412Cosnett JE. The origins of intravenous fluid therapy. Lancet. 1989 Apr 8;1(8641):768-71. doi: 10.1016/s0140-6736(89)92583-x. No abstract available.
PubMed 2564573Vermeulen LC Jr, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med. 1995 Feb 27;155(4):373-9. doi: 10.1001/archinte.155.4.373.
PubMed 7848020Weinstein PD, Doerfler ME. Systemic complications of fluid resuscitation. Crit Care Clin. 1992 Apr;8(2):439-48.
PubMed 1568149Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F; Danish Study Group on Perioperative Fluid Therapy. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg. 2003 Nov;238(5):641-8. doi: 10.1097/01.sla.0000094387.50865.23.
PubMed 14578723Brandstrup B, Beier-Holgersen R, Iversen LH, Starup CB, Wentzel LN, Lindorff-Larsen K, Petersen TC, Tonnesen H. The Influence of Perioperative Fluid Therapy on N-terminal-pro-brain Natriuretic Peptide and the Association With Heart and Lung Complications in Patients Undergoing Colorectal Surgery: Secondary Results of a Clinical Randomized Assessor-blinded Multicenter Trial. Ann Surg. 2020 Dec;272(6):941-949. doi: 10.1097/SLA.0000000000003724.
PubMed 31850996
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perioperative Fluid Treatment in Colorectal Surgery
- ClinicalTrials.gov ID
- NCT03537989
- Acronym / sponsor ID
- 1
- Conditions
- Colorectal Surgery, Postoperative Complications
- Keywords
- fluid therapy, Restricted fluid therapy, saline
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 172 participants (actual)
- Lead sponsor
- Holbaek SygehusUniversity, hospital or other
- Collaborators
- Bispebjerg Hospital, University Hospital, Gentofte, Copenhagen, Glostrup University Hospital, Copenhagen, Herlev Hospital, Hillerod Hospital, Denmark, Vejle Hospital, Aalborg University Hospital, Zealand University Hospital
- Study start
- 1 Nov 1999 (actual)
- Primary completion
- 31 Aug 2001 (actual)
- Study completion
- 31 Aug 2001 (actual)
- First posted
- 25 May 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a protocol for a trial carried out from 1999 to 2002. At that time, surgical patients received a large volume of intravenous saline during operations on the colon or the rectum, often so much fluid that their bodyweight increased by 4-6 kilograms. We hypothesized; that a restricted fluid regimen could prevent the development of cardiopulmonary complications and improve wound healing including the healing of an anastomosis of the gut.
We designed a clinical randomized assessor blinded multi-center trial comparing a restricted fluid regimen to a standard fluid regimen, the difference being the volume of saline administered to the patients. Patients undergoing surgery on the colon or the rectum were included after informed oral and written consent.
The restricted regimen aimed at zero-fluid balance with allowance for a body weight increase of 1 kg. The standard regimen was a bit "dryer" than the actual standard; our patients in the standard group received saline causing a body weight increase of only 3-4 kg. The fluid therapy started at midnight the day of operation, went on through the operation and continued on the wards until discharge. The patients were encouraged to eat and drink as much and as soon as possible after the operation.
The primary outcome was the number of patients who died or suffered a complication measured within 30 days of surgery. We looked at all complications, but especially heart and lung complications and complications related to the healing of wounds and anastomosis.
The patients was examined in the outpatient clinic after 30 days, and in addition, blinded assessors were reviewing the medical files for registration of postoperative complications.
The results are published in The Annals of Surgery 2003; 238(5)641-48. The restricted regimen nearly halved the number of patients with complications, and heart and lung complications were almost eliminated.
Other investigators confirmed the results, and a more restricted approach to fluid therapy to surgical patients has been implemented worldwide.
Detailed description
Aim:
To show the effect of a restrictive fluid regime compared to a standard regime by the frequency of complications in patients undergoing colorectal surgery.
Background:
Previous studies have risen suspicions of fluid balance, and especially a large amount of water and NaCl administration, can be a significant factor in developing postoperative complications (1, 2).
In 1990 in Critical Care Magazine, Lowell et al. described patients who in transferring to intensive therapy had an increased weight of > 10% of their preoperative weight, had a significantly higher mortality rate of 31.6 % than patients with an increased weight of < 10%, who only had a mortality rate of 10.3 %.
Some studies, have described, how all patients undergoing gastroenterological operations increase their body weight by 2-4% of the preoperative weight during the first 24 hours following surgery due to the perioperative saline intravenously (2, 3). The patients have been given a median of 6-7 L saline intravenously during the day of operation. This is fully comparable to other studies (3, 5).
Based on previous guidelines in anesthesiological departments, a volume of saline of 15 ml/kg bodyweight was administered during the first hour of surgery, and 7.5 ml/kg during the following hours. Furthermore, any blood loss was replaced by 2.5 ml saline per ml blood lost (6-9).
The patients in the study by Beier-Holgersen et al. returned to their preoperative weight after 4-5 days. In this material of 60 patients, six patients developed leakage of the bowel anastomosis, and two patients died from AMI and ARDS. Nine patients with severe complications had a weight gain of 6-14%.
The increased postoperative fluid retention results in increased universal edema, which can significantly affect the tissue's microcirculation and oxygenation. This may have influenced the healing of intestinal anastomoses and the development of cardiovascular and pulmonary complications, which typically occurred during the third postoperative day. Based on this, it is therefore relevant to investigate whether perioperative intervention against fluid administration can improve the postoperative course.
Design:
Prospective randomized multicenter study with stratification for each center. Block randomization with four patients per block. It is necessary to incorporate several centers for the investigation to be finished within a reasonable time.
Material:
Two x 70 patients scheduled for colorectal resection. The number is determined from previous works (1, 2) finding a total complication rate of at least 30% after colorectal resection in post-operatively early-nourished patients. The investigators wish to reduce this to 10% (MIREDIF = 20%). The risk of Type 1 error (5%) is set low to avoid overlooking a possible gain. The risk of Type 2 error is set at 20% (power at 80%).
As the material is unlikely to meet the normal distribution, the number of participant's increases to 70 in each group, i.e. 140 patients must be included. In order to reduce the variation, each center must include at least 16 patients (which means that up to nine centers have to participate).
Method:
- Patients are included preoperatively after informed consent. An investigator at the local center randomize the patients to either standard fluid treatment or restrictive perioperative fluid treatment. The main difference between the two regimes is that less isotonic saline is administered in the restrictive regime. Anesthesia and postoperative nutrition regimes are the same in the two groups. The patients are ASA and Apache 2 scored.
- Weight registration: The patient is weighed on the same set of scales at the time of hospitalization (entry weight), after bowel cleansing, and in the morning on the day of operation (preoperative weight). Hereafter daily weighing every postoperative morning.
- Blood tests: Blood is withdrawn on the day of hospitalization, on the day of operation in the morning, on arrival in the recovery ward and the following 7 days (or until discharged).
- Anesthesia: Patients must fast for food from midnight before surgery, but they can have clear fluids up to 2 hours preoperatively, but max. 500 ml from midnight. Premedication is a tablet of Triazolam 0.125 mg with 50-100 ml of water by mouth. Combined epidural and general anesthesia are used: An epidural catheter is inserted corresponding to TH10-12, tested with Lidocaine 2% and adrenaline 3-4 ml. After 3-5 minutes this is supplemented with refracted doses of Bupivacaine 0.5% until the blockade is sufficient (often about 8-12 ml). Continuous infusion of Bupivacain is administered 0.5%, 4-8 ml/hour. Finally, a bolus injection of 2 mg Morphine is administered. General anesthesia is induced with Fentanyl 5μg/kg, Thiopental 3-4 mg/kg and Rocuronium (Esmeron®) 0.6 mg/kg (all doses are modified according to each patient's needs and cardiovascular condition). Anesthesia is maintained with Isoflurane 0.2-0.4% end-tidal concentration in oxygen / atmospheric air (inspiratory oxygen concentration 30-35%). The neuromuscular block can be reverted with neostigmine when needed. Hypotension Diagnosis and Treatment: Detailed guidelines for clinical treatment and handling are given in the case report forms (CRF).
- Perioperative fluid treatment: During operation, fluid is submitted and recorded in the CRF. Fluid balance is calculated at the end of anesthesia.
- Monitoring: Standard anesthesia monitoring as recommended by Danish Anesthesiological Society. A central vein catheter (CVK) is placed if needed after the initiation of anesthesia to measure central venous pressure (CVP) until the patient is discharged from the recovery ward. Arterial blood gases and hematocrit are withdrawn immediately after the initiation of anesthesia, immediately after arriving at the recovery ward and before the patient is transferred to the surgical ward, in addition to clinical needs.
- Surgery: Surgery is performed in accordance with the department's routines. During the surgery, a nutritional feeding tube is inserted in the duodenum for postoperative enteral nutrition. If the tube cause nausea, the tube is removed and the patient will consume nutrition according to ability by mouth. Antibiotic prophylaxis, bowel cleansing, physiotherapy, etc. follow the usual guidelines of the respective departments.
- Postoperative fluid treatment and nutrition during the day of operation: Fluid recordings continue from the end of the anesthesia, on the recovery ward and for the rest of the day of operation. On the day of operation, 600 ml of Nutri-concentrated 75 is given in the feeding tube. Nutri-concentrated 75 contains 200 kcal and 7.5 g protein per 100 ml. 1000 ml pr. Day cover the recommended daily allowances for vitamins and minerals.
- Fluid treatment and nutrition in the following days: Nutri-concentrated 75® 1000 ml/day is continued the first three postoperative days. Thereafter the patient is expected to eat normally. The fluid regime in the restrictive group assessed based on the patient's weight, ability to drink independently and blood samples. The standard regime follows the department's usual postoperative regime.
- Postoperative analgesia: The basis is an epidural infusion of the standard mixture of Bupivacain-Morphine (5 mg Morphine + 250 mg Bupivacain in NaCl to the volume of 100 ml), 4-8 ml/hour. In addition, Morphine 5-10 mg p.n. If there are no contraindications, Paracetamol or NSAID can be administered (orally or rectally). The epidural pain treatment is continued postoperatively for a maximum of 4 days, after which the epidural catheter is removed. If the patient need analgesics hereafter, opioid is given by mouth or intravenously as well as Paracetamol and/or NSAIDs.
- For the treatment of nausea the following may be given: Ondansetron (Zofran®), Cisapride (Prepulsid®), Metoclopramide (Primperan®) or DHB.
- A postoperative outpatient visit with the investigating doctor is planned 4 weeks after the surgery. Postoperative complications are registered.
Ethics:
Participation in the project is voluntary and inclusion is after informed consent. Consent can be withdrawn at any time without further explanation, and without this affecting the patient's treatment in any way.
There is no risk associated with participation in the project, but discomfort associated with additional blood sampling for the project, no more than 4-5 times. However, these blood samples will preferably be taken from the CVK, so the patient avoids being stabbed unnecessarily.
In the long term, a treatment benefit is possible and this appears to outweigh the discomfort mentioned above.
The project is registered with the Scientific Ethics Committee (multicenter study) and The Danish Data registration agency in accordance with applicable guidelines. All person-identifiable data is destroyed after the project is completed.
Addendum to the protocol written during the patient inclusion and before the trial was completed.
Hypothesis:
Both too little and too much fluid administered intravenously may be harmful to the cardiac function (low oxygen supply and congestion) and cause cardiovascular complications: Postoperatively developed arrhythmias, AMI, pneumonia, pulmonary congestion, postoperatively developed pleural exudate, pulmonary edema or ARDS.
Both too little and too much fluid administered intravenously may be harmful to tissue healing (low oxygen supply and interstitial edema) and cause complications related to tissue healing and infection: Infections of the wound, bursting of the wound (superficial and deeper), leakage from the anastomosis and separation of stoma.
Randomization:
The investigating surgeon or anesthesiologist perform the randomization by opening consecutively numbered opaque envelopes. The randomization is stratified for each center and for colonic and rectal surgery the latter by opening an envelope with highest number for rectal surgical patients, and with lowest number for colonic patients.
Blinding:
Specialist surgeons reading the medical journals censored for all information about randomization group, fluid therapy given or bodyweight measurements will perform a blinded assessment for the primary outcome.
Two doctors will evaluate each patient file, and in case of disagreement, a third will decide the outcome.
Plan for analysis:
An intention to treat analysis will be performed for the primary outcome for all patients included in the trial whether or not they met a post randomization exclusion criterion, and therefore did or did not receive the allocated treatment.
A per protocol analysis will be performed for the primary outcome for all patients fulfilling the in- and exclusion criteria whether or not they adhered to the protocol.
Subgroup analysis will be performed for the patients with Major-, Minor-, Cardio-pulmonic- and tissue-healing complications.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Restricted group | Experimental | Drug: SalineOral fluid to 2 h before surgery. Intra-operatively: Glucose 5% (500 ml - volume drunk during fast); HAES 6% for blood loss volume to volume; IV-medicine in saline 0.9% for anesthesia and antibiotics. Blood products after current rules. Postoperatively: 1000 ml glucose containing fluid in the recovery room. Free oral intake of fluid and food as well as enteral feeding by tube 500 ml. In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. If less than 1500 ml fluid pr. mouth supplement with VI-fluid. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Goal: zero fluid balance with up to 1-kilogram body weight increase. Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid. |
| Standard group | Active comparator | Drug: SalineOral fluid to 2 h before surgery. Intra-operatively: Saline 500 ml for fasting; 500 ml HAES 6% for the epidural, Saline for the third space: 7 ml/kg/h first hour, 5 ml/kg/h 2.-3. Hour, 3 ml/kg/h subsequent hours. 1000-1500 ml Saline replaced lost blood up to 500 ml, additional HAES 6% for additional blood loss; IV-medicine in saline. Postoperatively: 1000-2000 ml isotonic fluid in the recovery room. Free oral fluid and food as well as enteral feeding by tube 500 ml. In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. Supplemental iv-fluid according to department rules. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients scheduled for planned surgery on the colon or the rectum
- ASA group 1-3
Key exclusion criteria (9 listed)
- Patients unable to give informed consent (mental disorders, dementia, language problems)
- Diabetes mellitus
- Renal insufficiency
- Disseminated cancers or secondary cancers
- Inflammatory bowel disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SalineAlso: NaCl 0.9%To reduce the volume of saline administered during surgery of the colon and the rectum | Drug | Restricted group, Standard group |
Primary outcome
Postoperative complications and mortality
Time frame: After 30 days of follow-up
The complications was defined by protocol.
2 secondary outcomes
Cardiopulmonary complications
Time frame: After 30 days of follow-up
Complications related to tissue healing
Time frame: After 30 days of follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2018.
- Background: PubMed 2364713Lowell JA, Schifferdecker C, Driscoll DF, Benotti PN, Bistrian BR. Postoperative fluid overload: not a benign problem. Crit Care Med. 1990 Jul;18(7):728-33. doi: 10.1097/00003246-199007000-00010.
- Background: PubMed 9038665Beier-Holgersen R, Boesby S. Influence of postoperative enteral nutrition on postsurgical infections. Gut. 1996 Dec;39(6):833-5. doi: 10.1136/gut.39.6.833.
- Background: PubMed 3947870Nielsen OM, Engell HC. Increased glomerular filtration rate in patients after reconstructive surgery on the abdominal aorta. Br J Surg. 1986 Jan;73(1):34-7. doi: 10.1002/bjs.1800730113.
- Background: PubMed 8966776Rasmussen LA, Rosenberg J, Crawford ME, Kehlet H. [Perioperative fluid therapy. A quality control study]. Ugeskr Laeger. 1996 Sep 16;158(38):5286-90. Danish.
- Background: PubMed 8937412Vamvakas EC, Carven JH, Hibberd PL. Blood transfusion and infection after colorectal cancer surgery. Transfusion. 1996 Nov-Dec;36(11-12):1000-8. doi: 10.1046/j.1537-2995.1996.36111297091746.x.
- Background: PubMed 2564573Cosnett JE. The origins of intravenous fluid therapy. Lancet. 1989 Apr 8;1(8641):768-71. doi: 10.1016/s0140-6736(89)92583-x. No abstract available.
- Background: PubMed 7848020Vermeulen LC Jr, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med. 1995 Feb 27;155(4):373-9. doi: 10.1001/archinte.155.4.373.
- Background: PubMed 1568149Weinstein PD, Doerfler ME. Systemic complications of fluid resuscitation. Crit Care Clin. 1992 Apr;8(2):439-48.
- Results publication: PubMed 14578723Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F; Danish Study Group on Perioperative Fluid Therapy. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg. 2003 Nov;238(5):641-8. doi: 10.1097/01.sla.0000094387.50865.23.
- Derived from this study: PubMed 31850996Brandstrup B, Beier-Holgersen R, Iversen LH, Starup CB, Wentzel LN, Lindorff-Larsen K, Petersen TC, Tonnesen H. The Influence of Perioperative Fluid Therapy on N-terminal-pro-brain Natriuretic Peptide and the Association With Heart and Lung Complications in Patients Undergoing Colorectal Surgery: Secondary Results of a Clinical Randomized Assessor-blinded Multicenter Trial. Ann Surg. 2020 Dec;272(6):941-949. doi: 10.1097/SLA.0000000000003724.
- Individual participant dataSharing planned: Undecided. We do not mind sharing the data
Related trials for Colorectal Surgery
RecruitingObservational study
Evaluation for NCI Surgery Branch Clinical Research Protocols
Synovial Cell Cancer, Melanoma
RecruitingObservational study
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Colorectal Neoplasms, Gastric Neoplasms
RecruitingPhase 1
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Not yet recruitingObservational study
Cost-utility Evaluation of Cytoreductive Surgery With or Without Mitomycin-C Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Resectable Colorectal Peritoneal Metastases
Hyperthermic Intraperitoneal Chemotherap, Colorectal Cancer Metastatic
Not yet recruiting
T1 Colorectal Cancer After Local Excision: Decision Between Surgery and Active Surveillance (T1LDA Trial)
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Birgitte Brandstrup, PhD principal investigator
Holbaek Hospital
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Saline in people with Colorectal Surgery and Postoperative Complications, run by Holbaek Sygehus.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative complications and mortality (time frame: After 30 days of follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03537989, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2018.